GlobeNewswire Inc.··IpsenIpsen's IQIRVO Shows Strong Real-World Efficacy in PBC Treatment Beyond Trials
Ipsen's IQIRVO shows 67% fatigue improvement vs. 31% placebo in Phase III, with real-world data confirming 59% ALP normalization and favorable tolerability in routine clinical practice.
IPSEYclinical trial resultsPPAR agonist